Compare PFLT & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PFLT | CTMX |
|---|---|---|
| Founded | 2010 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 742.1M | 716.9M |
| IPO Year | 2010 | 2015 |
| Metric | PFLT | CTMX |
|---|---|---|
| Price | $7.46 | $3.75 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 10 |
| Target Price | $10.50 | ★ $12.10 |
| AVG Volume (30 Days) | 878.5K | ★ 2.7M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | ★ 14.12% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $76,201,000.00 |
| Revenue This Year | $8.16 | N/A |
| Revenue Next Year | N/A | $7.61 |
| P/E Ratio | $24.14 | ★ $22.58 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.83 | $1.90 |
| 52 Week High | $10.29 | $8.21 |
| Indicator | PFLT | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 54.57 | 61.85 |
| Support Level | $7.03 | $3.66 |
| Resistance Level | $7.67 | $3.96 |
| Average True Range (ATR) | 0.12 | 0.19 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 78.69 | 80.42 |
PennantPark Floating Rate Capital Ltd is a closed-end, externally managed, non-diversified investment company. Its investment objectives are to generate both current income and capital appreciation by investing in Floating Rate Loans and other investments made to U.S. middle-market companies. The company believes that Floating Rate Loans to U.S. middle-market companies offer attractive risk-reward to investors due to the limited amount of capital available for such companies and the potential for rising interest rates. The company generates revenue in the form of interest income on the debt securities and dividends.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.